Billionaire investor Leon Cooperman gave 12 stock recommendations at the Delivering Alpha conference Wednesday.» Read More
NEW YORK, July 28- Pfizer Inc's vulnerability to cheaper generics and its weak roster of experimental medicines will be on display Tuesday when the company reports quarterly earnings, reviving interest in its pursuit of AstraZeneca Plc or other deals to fortify its pipeline.
Abbvie Inc.' s deal to combine with Shire PLC would be the largest made so far this year, excluding assumed debt.
NEW YORK, July 16- Hedge fund manager Leon Cooperman, who has forecast that the Standard& Poor's 500 stock index will hit 2000 this year, cautioned on Wednesday that gains will be slower as the market is more fairly valued now.
July 14- Several multi-billion dollar deals and bids have made 2014 a busy year for healthcare acquisitions, despite Pfizer pulling its $118 billion offer for AstraZeneca.
U.S. generic drugmaker Mylan is said to be in advanced talks to buy a multibillion-dollar portfolio of established products from Abbott Laboratories.
Medical technology group Medtronic Inc said last month that it plans to buy Covidien Plc, a rival based in low-tax Ireland. The research service said other inversions have been done in the past decade by Mallinckrodt Pharmaceuticals, Perrigo Co Plc, Actavis Plc and other companies, many of them rebasing for tax purposes to Ireland.
WASHINGTON, June 30- Generic drugmaker Actavis Plc has won U.S. approval to buy specialty pharmaceuticals company Forest Laboratories on condition it sell or relinquish the rights to four generic medicines, the Federal Trade Commission said on Monday.
June 26- Acorda Therapeutics Inc said Actavis Plc plans to market a generic version of Acorda's multiple sclerosis treatment, Ampyra. Ampyra, which was approved in January 2010, had net sales of $72.5 million in the first quarter ended March 31.
*Move bolsters Shire in defence against AbbVie. *AbbVie to put its case to Shire shareholders- source. LONDON, June 25- Shire, which has spurned a $46 billion takeover offer from U.S. group AbbVie as inadequate, has a new reason to argue it is worth more after a U.S. court backed patent claims on its top-selling drug Vyvanse.
June 3- The city of Chicago has filed a lawsuit against five large narcotics makers alleging they contributed to the country's prescription drug epidemic by deceptively promoting their painkillers.
China has been a magnet for the big global pharmaceutical companies and other healthcare firms as growth slows in Europe and the United States. While global drugmakers withhold their China profit figures, the analysis suggests profit growth is harder to come by- a concern as many global firms look to China as a future growth driver.
LONDON, May 15- Eli Lilly said on Thursday it had lost a patent case in the English High Court over its blockbuster Alimta lung cancer drug to generic drugmaker Actavis.
*Vivus has 7 U.S. patents for Qsymia, earliest expires in June 2020. May 9- Vivus Inc said on Friday drugmaker Actavis Plc plans to market a generic version of Vivus's obesity drug Qsymia that was approved in July 2012.
May 9- Vivus Inc said on Friday drugmaker Actavis Plc plans to market a generic version of Vivus's obesity drug Qsymia that was approved in July 2012. Actavis had filed a U.S. marketing application for its generic version of the diet pill, according to a notice sent by the generic drugmaker on May 7, Vivus said.
MAY May 6- Merck& Co Inc agrees to sell its consumer care business to Germany's Bayer AG for $14.2 billion. May 2- Pfizer Inc raises its offer for AstraZeneca Plc to 63 billion pounds, but the British company promptly rejects the proposal, which would create the world's biggest pharmaceuticals company.
NEW YORK, May 1- Rumors about a massive healthcare deal were circulating in industry circles, months before Pfizer Inc disclosed its $100 billion pursuit of Britain's AstraZeneca Plc, according to several industry bankers and lawyers.
Wall Street has its eye on the Federal Reserve's meeting, but a slew of data is likely to have more influence on stocks Wednesday.
**U.S. drugmaker Pfizer said on April 28 that it had offered to buy Britain's AstraZeneca Plc in January for about $98.9 billion, or nearly 47 pounds per share.
April 28- Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. A similar lawsuit was announced Friday by Mylan Inc over generic drug marketing exclusivity for Celebrex.
April 28- Actavis Plc on Monday said it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.